Shares in IXICO PLC (LSE:IXI, OTC
HYOF) rose as much as 15% on Thursday after the neuroscience analytics group said it expects full-year revenues to exceed expectations, supported by strong sales momentum and a clearer path to profitability. The London-listed company, which provides artificial intelligence-based imaging and biomarker analysis for neurological drug development, said revenue for the year to 30 September will be at least £6.3 million, a 9% rise on the prior year and the highest since it adopted its current commercial strategy.
